BidaskClub cut shares of InVitae Corp (NASDAQ:NVTA) from a hold rating to a sell rating in a research note published on Thursday.

Several other analysts have also issued reports on NVTA. Benchmark Co. reaffirmed a buy rating and issued a $16.00 target price (up previously from $11.00) on shares of InVitae Corp in a research note on Monday, April 3rd. ValuEngine raised InVitae Corp from a strong sell rating to a sell rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research lowered InVitae Corp from a hold rating to a sell rating in a research note on Tuesday, July 18th. Four analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $12.69.

Shares of InVitae Corp (NASDAQ:NVTA) traded down 1.9990% on Thursday, reaching $9.3199. 109,084 shares of the company were exchanged. The stock’s 50-day moving average is $9.47 and its 200 day moving average is $9.73. The firm’s market capitalization is $394.36 million. InVitae Corp has a 12-month low of $5.76 and a 12-month high of $11.88.

InVitae Corp (NASDAQ:NVTA) last issued its earnings results on Tuesday, May 9th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.04. The business had revenue of $10.34 million during the quarter, compared to analyst estimates of $10.90 million. InVitae Corp had a negative return on equity of 119.10% and a negative net margin of 260.48%. InVitae Corp’s revenue for the quarter was up 161.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.80) earnings per share. On average, analysts forecast that InVitae Corp will post ($2.39) EPS for the current year.

WARNING: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/invitae-corp-nasdaqnvta-downgraded-to-sell-at-bidaskclub/1464204.html.

Several hedge funds have recently added to or reduced their stakes in NVTA. TIAA CREF Investment Management LLC raised its stake in InVitae Corp by 32.8% in the first quarter. TIAA CREF Investment Management LLC now owns 121,549 shares of the medical research company’s stock worth $1,344,000 after buying an additional 30,039 shares during the period. Wellington Management Group LLP raised its stake in InVitae Corp by 0.6% in the first quarter. Wellington Management Group LLP now owns 3,974,227 shares of the medical research company’s stock worth $43,955,000 after buying an additional 25,100 shares during the period. American International Group Inc. raised its stake in InVitae Corp by 31.3% in the first quarter. American International Group Inc. now owns 17,174 shares of the medical research company’s stock worth $190,000 after buying an additional 4,090 shares during the period. Trexquant Investment LP bought a new stake in InVitae Corp during the first quarter worth $200,000. Finally, Gamco Investors INC. ET AL bought a new stake in InVitae Corp during the first quarter worth $316,000.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.